Literature DB >> 29113801

Producing a glycosylating Escherichia coli cell factory: The placement of the bacterial oligosaccharyl transferase pglB onto the genome.

Benjamin Strutton1, Stephen R P Jaffé1, Jagroop Pandhal1, Phillip C Wright2.   

Abstract

Although Escherichia coli has been engineered to perform N-glycosylation of recombinant proteins, an optimal glycosylating strain has not been created. By inserting a codon optimised Campylobacter oligosaccharyltransferase onto the E. coli chromosome, we created a glycoprotein platform strain, where the target glycoprotein, sugar synthesis and glycosyltransferase enzymes, can be inserted using expression vectors to produce the desired homogenous glycoform. To assess the functionality and glycoprotein producing capacity of the chromosomally based OST, a combined Western blot and parallel reaction monitoring mass spectrometry approach was applied, with absolute quantification of glycoprotein. We demonstrated that chromosomal oligosaccharyltransferase remained functional and facilitated N-glycosylation. Although the engineered strain produced less total recombinant protein, the glycosylation efficiency increased by 85%, and total glycoprotein production was enhanced by 17%.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Absolute quantification glycoprotein; Bacterial N-linked glycosylation; Escherichia coli; Glycoprotein producing host strain; Glycosylation efficiency; Oligosaccharyl transferase

Mesh:

Substances:

Year:  2017        PMID: 29113801     DOI: 10.1016/j.bbrc.2017.11.023

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Production of Vaccines Using Biological Conjugation.

Authors:  Emily J Kay; Vanessa S Terra
Journal:  Methods Mol Biol       Date:  2022

2.  Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines.

Authors:  Emily J Kay; Marta Mauri; Sam J Willcocks; Timothy A Scott; Jon Cuccui; Brendan W Wren
Journal:  Microb Cell Fact       Date:  2022-04-21       Impact factor: 6.352

Review 3.  Recent advances in the production of recombinant glycoconjugate vaccines.

Authors:  Emily Kay; Jon Cuccui; Brendan W Wren
Journal:  NPJ Vaccines       Date:  2019-05-01       Impact factor: 7.344

4.  An Engineered Pathway for Production of Terminally Sialylated N-glycoproteins in the Periplasm of Escherichia coli.

Authors:  Jing Zhu; Yao Ruan; Xin Fu; Lichao Zhang; Gaoshun Ge; J Gerard Wall; Teng Zou; Yang Zheng; Ning Ding; Xuejun Hu
Journal:  Front Bioeng Biotechnol       Date:  2020-04-15

5.  Genetic and process engineering strategies for enhanced recombinant N-glycoprotein production in bacteria.

Authors:  Fenryco Pratama; Dennis Linton; Neil Dixon
Journal:  Microb Cell Fact       Date:  2021-10-14       Impact factor: 5.328

Review 6.  Strategies for efficient production of recombinant proteins in Escherichia coli: alleviating the host burden and enhancing protein activity.

Authors:  Zi-Xu Zhang; Fang-Tong Nong; Yu-Zhou Wang; Chun-Xiao Yan; Yang Gu; Ping Song; Xiao-Man Sun
Journal:  Microb Cell Fact       Date:  2022-09-15       Impact factor: 6.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.